众生药业2025年第三季度净利润2.51亿元 同比增长68.40%

Core Insights - Guangdong Zhongsheng Pharmaceutical Co., Ltd. reported a revenue of 1.889 billion yuan for the first three quarters of 2025, a year-on-year decrease of 1.01%, while net profit attributable to shareholders increased by 68.40% to 251 million yuan [2] Group 1: Financial Performance - The company achieved a revenue of 1.889 billion yuan, reflecting a slight decline of 1.01% compared to the previous year [2] - Net profit attributable to shareholders reached 251 million yuan, marking a significant increase of 68.40% year-on-year [2] Group 2: Business Strategy - Zhongsheng Pharmaceutical employs a synergistic strategy across research, production, and sales, focusing on operational optimization and cost control [2] - The company aims to enhance its core competitiveness in the pharmaceutical market through breakthroughs in research, reliable production, and sales growth [2] Group 3: Product Development - Zhongsheng Pharmaceutical is the only domestic company with innovative drugs for both COVID-19 and influenza [2] - The company is actively advancing the commercialization of its products, Le Rui Ling® and An Rui Wei®, to promote integrated prevention and treatment of COVID-19 and influenza [2] - The company is enhancing marketing innovation through academic ecosystem construction, data service upgrades, and key project practices [2] Group 4: Research and Innovation - The company focuses on independent research and development, integrating internal and external resources for innovative drug research [2] - Zhongsheng Pharmaceutical leverages its advantages in small molecules and peptide drug research platforms to develop differentiated early-stage pipelines in respiratory and metabolic diseases [2]